Affordable Access

deepdyve-link
Publisher Website

Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.

Authors
  • Matthews, Kellie1
  • Noker, Patricia E
  • Tian, Baohong
  • Grimes, Sheila D
  • Fulton, Ronna
  • Schweikart, Karen
  • Harris, Raymond
  • Aurigemma, Rose
  • Wang, Minghui
  • Barnes, Mack N
  • Siegal, Gene P
  • Hemminki, Akseli
  • Zinn, Kurt
  • Curiel, David T
  • Alvarez, Ronald D
  • 1 Division of Gynecologic Oncology, University of Alabama at Birmingham, Alabama, USA. [email protected]
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Jun 15, 2009
Volume
15
Issue
12
Pages
4131–4137
Identifiers
DOI: 10.1158/1078-0432.CCR-08-3354
PMID: 19509153
Source
Medline
License
Unknown

Abstract

These studies provide justification for planned dosing of Ad5.SSTR/TK.RGD for a planned phase I clinical trial and insights regarding anticipated toxicity.

Report this publication

Statistics

Seen <100 times